DEGNAN CHRIS (Chief Financial Officer) sold 32.6% of their position (2.20K shares) of UROGEN PHARMA LTD. on the open market
Open‑market sale worth $80.8K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 10/9/2026ACC: 0001437749-26-032421
Officer· Chief Financial Officer
Since Jan 2026
-2.20K
Net shares
Net seller
$80.8K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
4.48K acquired · 6.68K disposed
Non-Derivative Transactions2
Ordinary Shares
Direct
Shares
+4.48K
Price / share
—
Trade value
—
% of position
196.6%
10/8/2026
2.28K→6.76K
Ordinary Shares
Direct
Shares
−2.20K
Price / share
$36.69
Trade value
$80.79K
% of position
32.6%
10/8/2026
6.76K→4.56K
Total
Net shares
+2.28K
Net value
-$80.79K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 10/8/2026 | M · Option Exercise | +4.48K | — | — | 196.6% | 2.28K | 6.76K |
| Ordinary Shares Direct | 10/8/2026 | S · Sale | −2.20K | $36.69 | $80.79K | 32.6% | 6.76K | 4.56K |
| Total | +2.28K | -$80.79K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Ordinary Shares
4.48K shares
Shares
−4.48K
Strike price
Held after
4.48K
Exercisable
—
10/8/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Ordinary Shares4.48K shares | 10/8/2026 | M · Option Exercise | −4.48K | — | 4.48K |